Published Date: 25 Mar 2025
Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 days after diagnosis to have surgery, according to newly published research from the University of ...
Read Full NewsPublished phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.
Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders
Iron Polymaltose Complex Outperforms Liposomal Iron in Pediatric CKD Anemia
FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies
Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates
1.
Studies show that treatment for non-Hodgkin's lymphoma is also focused on the lymphoma.
2.
An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.
3.
La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.
4.
New analysis helps discern benign from malignant thyroid growths
5.
To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.
1.
Exploring the Causes and Treatment of Granulocytopenia: A Comprehensive Guide
2.
Exploring the Potential of Xospata: A New Frontier in Cancer Treatment
3.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
4.
From Muscle Soreness to Improved Endurance: The Benefits of Monitoring Lactic Acid Levels
5.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation